683 Capital Management LLC Stake in Alnylam Pharmaceuticals INC (ALNY) Decreased as Valuation Rose

March 14, 2018 - By Adrian Mccoy

Investors sentiment decreased to 0.92 in 2017 Q3. Its down 0.60, from 1.52 in 2017Q2. It dropped, as 30 investors sold ALNY shares while 73 reduced holdings. 40 funds opened positions while 55 raised stakes. 86.02 million shares or 0.72% more from 85.40 million shares in 2017Q2 were reported. Arrowstreet Capital Partnership invested in 51,485 shares or 0.02% of the stock. Legal General Grp Incorporated Pcl invested in 32,360 shares. Tiaa Cref Invest Management Limited Liability has invested 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Vantage Inv Limited Liability Corporation holds 155 shares or 0% of its portfolio. Cubist Systematic Strategies Ltd Liability holds 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 792 shares. Susquehanna Gp Llp stated it has 10,876 shares or 0% of all its holdings. 13,012 are owned by Macquarie Gp Ltd. 173,450 were accumulated by Deutsche State Bank Ag. Schwab Charles Invest Mgmt Incorporated holds 0.03% or 244,550 shares in its portfolio. Aperio Lc has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 16,908 shares. Perceptive Advsr Limited Liability Com stated it has 8.02% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 155,185 were accumulated by Van Eck Corporation. Pnc Financial Svcs Group Inc holds 8,799 shares. 784,619 were accumulated by First Limited Partnership. Royal National Bank Of Canada has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Since September 20, 2017, it had 0 insider buys, and 3 sales for $23.18 million activity. Mason Michael had sold 36,745 shares worth $4.84M on Thursday, January 4.

683 Capital Management Llc decreased its stake in Alnylam Pharmaceuticals Inc (ALNY) by 11.3% based on its latest 2017Q3 regulatory filing with the SEC. 683 Capital Management Llc sold 30,500 shares as the company’s stock rose 48.45% with the market. The hedge fund held 239,500 shares of the health care company at the end of 2017Q3, valued at $28.14M, down from 270,000 at the end of the previous reported quarter. 683 Capital Management Llc who had been investing in Alnylam Pharmaceuticals Inc for a number of months, seems to be less bullish one the $14.13 billion market cap company. The stock decreased 1.71% or $2.46 during the last trading session, reaching $141.7. About 667,406 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since March 14, 2017 and is uptrending. It has outperformed by 16.84% the S&P500.

683 Capital Management Llc, which manages about $566.08 million and $951.63M US Long portfolio, upped its stake in Alps Etf Tr (AMLP) by 440,000 shares to 1.01M shares, valued at $11.33 million in 2017Q3, according to the filing. It also increased its holding in Cars Com Inc by 491,449 shares in the quarter, for a total of 750,000 shares, and has risen its stake in Procter And Gamble Co (Put) (NYSE:PG).

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on May, 4. They expect $-1.48 earnings per share, down 18.40 % or $0.23 from last year’s $-1.25 per share. After $-1.48 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “2018 Brings New Challenges And Opportunities For Alnylam Pharmaceuticals” on February 20, 2018, also Businesswire.com with their article: “Alnylam Unveils Resources to ‘Bridge the Gap’ in Knowledge of Hereditary ATTR …” published on March 13, 2018, Businesswire.com published: “Alnylam Retains Global Rights to Lumasiran, an Investigational RNAi …” on March 12, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Zacks.com and their article: “Alnylam Pharmaceuticals (ALNY) Up 1.6% Since Earnings Report: Can It Continue?” published on March 12, 2018 as well as Fool.com‘s news article titled: “Alnylam Pharmaceuticals Starts the Wait for Approval” with publication date: February 12, 2018.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 99 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating by Cowen & Co given on Thursday, September 7. As per Thursday, October 6, the company rating was maintained by Goldman Sachs. Cowen & Co maintained the shares of ALNY in report on Monday, June 26 with “Buy” rating. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Piper Jaffray on Friday, November 17. Morgan Stanley maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Thursday, September 21. Morgan Stanley has “Equal-Weight” rating and $101 target. The rating was maintained by FBR Capital with “Buy” on Friday, January 19. The firm has “Buy” rating given on Thursday, November 2 by Piper Jaffray. The stock has “Buy” rating by Chardan Capital Markets on Monday, December 19. Jefferies initiated the shares of ALNY in report on Friday, October 23 with “Buy” rating. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Chardan Capital Markets on Monday, June 12.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: